New Insights on the Mechanisms of Myocardial Injury in Hypertensive Patients With COVID-19

Purpose: Myocardial injury is common in hypertensive patients with 2019 coronavirus disease (COVID-19). Immune dysregulation could be associated to cardiac injury in these patients, but the underlying mechanism has not been fully elucidated.

Methods: All patients were selected prospectively from a multicenter registry of adults hospitalized with confirmed COVID-19. Cases had hypertension and myocardial injury, defined by troponin levels above the 99th percentile upper reference limit, and controls were hypertensive patients with no myocardial injury. Biomarkers and immune cell subsets were quantified and compared between the two groups. A multiple logistic regression model was used to analyze the associations of clinical and immune variables with myocardial injury.

Results: The sample comprised 193 patients divided into two groups: 47 cases and 146 controls. Relative to controls, cases had lower total lymphocyte count, percentage of T lymphocytes, CD8CD38 mean fluorescence intensity (MFI), and percentage of CD8 human leukocyte antigen DR isotope (HLA-DR) CD38cells and higher percentage of natural killer lymphocytes, natural killer group 2A (NKG2A) MFI, percentage of CD8CD38cells, CD8HLA-DRMFI, CD8NKG2AMFI, and percentage of CD8HLA-DRCD38cells. On multivariate regression, the CD8HLA-DRMFI, CD8CD38MFI, and total lymphocyte count were associated significantly with myocardial injury.

Conclusion: Our findings suggest that lymphopenia, CD8CD38MFI, and CD8HLA-DRMFI are immune biomarkers of myocardial injury in hypertensive patients with COVID-19. The immune signature described here may aid in understanding the mechanisms underlying myocardial injury in these patients. The study data might open a new window for improvement in the treatment of hypertensive patients with COVID-19 and myocardial injury.

Citing Articles

Immune Profile and MRI-Detected Cardiac Fibrosis and Edema in Hypertensive and Non-Hypertensive Patients with COVID-19.

Moll-Bernardes R, Camargo G, Silvestre-Sousa A, Barroso J, Ferreira J, Tortelly M J Clin Med. 2024; 13(23).

PMID: 39685774 PMC: 11642154. DOI: 10.3390/jcm13237317.

Cardiac remodeling and inflammation detected by magnetic resonance imaging in COVID-19 survivors.

Schaustz E, Secco J, Barroso J, Ferreira J, Tortelly M, Pimentel A Int J Cardiol Heart Vasc. 2024; 54:101499.

PMID: 39280695 PMC: 11400604. DOI: 10.1016/j.ijcha.2024.101499.

References

Mehra M, Desai S, Kuy S, Henry T, Patel A . Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. 2020; 382(25):e102. PMC: 7206931. DOI: 10.1056/NEJMoa2007621. View

Li J, Wang X, Chen J, Zhang H, Deng A . Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiol. 2020; 5(7):825-830. PMC: 7180726. DOI: 10.1001/jamacardio.2020.1624. View

Lopes R, Macedo A, de Barros E Silva P, Moll-Bernardes R, Feldman A, Arruda G . Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial. Am Heart J. 2020; 226:49-59. PMC: 7219415. DOI: 10.1016/j.ahj.2020.05.002. View

Majure D, Gruberg L, Saba S, Kvasnovsky C, Hirsch J, Jauhar R . Usefulness of Elevated Troponin to Predict Death in Patients With COVID-19 and Myocardial Injury. Am J Cardiol. 2020; 138:100-106. PMC: 7550867. DOI: 10.1016/j.amjcard.2020.09.060. View

Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F . Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020; 5(7):802-810. PMC: 7097841. DOI: 10.1001/jamacardio.2020.0950. View

Aikawa T, Takagi H, Ishikawa K, Kuno T . Myocardial injury characterized by elevated cardiac troponin and in-hospital mortality of COVID-19: An insight from a meta-analysis. J Med Virol. 2020; 93(1):51-55. PMC: 7301031. DOI: 10.1002/jmv.26108. View

Visco V, Vitale C, Rispoli A, Izzo C, Virtuoso N, Ferruzzi G . Post-COVID-19 Syndrome: Involvement and Interactions between Respiratory, Cardiovascular and Nervous Systems. J Clin Med. 2022; 11(3). PMC: 8836767. DOI: 10.3390/jcm11030524. View

Li X, Guan B, Su T, Liu W, Chen M, Bin Waleed K . Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis. Heart. 2020; 106(15):1142-1147. PMC: 7295861. DOI: 10.1136/heartjnl-2020-317062. View

Moll-Bernardes R, Silvestre de Sousa A, Macedo A, Lopes R, Vera N, Maia L . IL-10 and IL-12 (P70) Levels Predict the Risk of Covid-19 Progression in Hypertensive Patients: Insights From the BRACE-CORONA Trial. Front Cardiovasc Med. 2021; 8:702507. PMC: 8353079. DOI: 10.3389/fcvm.2021.702507. View

10.

Moll-Bernardes R, Fortier S, Sousa A, Lopes R, Vera N, Conde L . NKG2A Expression among CD8 Cells Is Associated with COVID-19 Progression in Hypertensive Patients: Insights from the BRACE CORONA Randomized Trial. J Clin Med. 2022; 11(13). PMC: 9267446. DOI: 10.3390/jcm11133713. View

11.

Huang S, Wang J, Liu F, Liu J, Cao G, Yang C . COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. Hypertens Res. 2020; 43(8):824-831. PMC: 7261650. DOI: 10.1038/s41440-020-0485-2. View

12.

Gadotti A, Deus M, Telles J, Wind R, Goes M, Garcia Charello Ossoski R . IFN-γ is an independent risk factor associated with mortality in patients with moderate and severe COVID-19 infection. Virus Res. 2020; 289:198171. PMC: 7510544. DOI: 10.1016/j.virusres.2020.198171. View

13.

Li Q, Xu W, Li W, Huang C, Chen L . Dynamics of cytokines and lymphocyte subsets associated with the poor prognosis of severe COVID-19. Eur Rev Med Pharmacol Sci. 2020; 24(23):12536-12544. DOI: 10.26355/eurrev_202012_24051. View

14.

Jin M, Shi N, Wang M, Shi C, Lu S, Chang Q . CD45: a critical regulator in immune cells to predict severe and non-severe COVID-19 patients. Aging (Albany NY). 2020; 12(20):19867-19879. PMC: 7655207. DOI: 10.18632/aging.103941. View

15.

Del Valle D, Kim-Schulze S, Huang H, Beckmann N, Nirenberg S, Wang B . An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020; 26(10):1636-1643. PMC: 7869028. DOI: 10.1038/s41591-020-1051-9. View

16.

Hue S, Beldi-Ferchiou A, Bendib I, Surenaud M, Fourati S, Frapard T . Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2020; 202(11):1509-1519. PMC: 7706149. DOI: 10.1164/rccm.202005-1885OC. View

17.

Tavakolpour S, Rakhshandehroo T, Wei E, Rashidian M . Lymphopenia during the COVID-19 infection: What it shows and what can be learned. Immunol Lett. 2020; 225:31-32. PMC: 7305732. DOI: 10.1016/j.imlet.2020.06.013. View

18.

De Lama Caro-Paton G, Martinez de Azagra-Garde A, Garcia-Salido A, Cabrero-Hernandez M, Tamariz A, Nieto-Moro M . Shock and Myocardial Injury in Children With Multisystem Inflammatory Syndrome Associated With SARS-CoV-2 Infection: What We Know. Case Series and Review of the Literature. J Intensive Care Med. 2020; 36(4):392-403. DOI: 10.1177/0885066620969350. View

19.

Haroun R, Osman W, Eessa A . Interferon-γ-induced protein 10 (IP-10) and serum amyloid A (SAA) are excellent biomarkers for the prediction of COVID-19 progression and severity. Life Sci. 2021; 269:119019. PMC: 7832132. DOI: 10.1016/j.lfs.2021.119019. View

20.

Stumpf C, Auer C, Yilmaz A, Lewczuk P, Klinghammer L, Schneider M . Serum levels of the Th1 chemoattractant interferon-gamma-inducible protein (IP) 10 are elevated in patients with essential hypertension. Hypertens Res. 2011; 34(4):484-8. DOI: 10.1038/hr.2010.258. View